{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:41Z","timestamp":1792783361640,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Editorial Assistance Provided by LEO Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11657-020-00842-0","type":"journal-article","created":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T01:02:28Z","timestamp":1605315748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Plain vitamin D or active vitamin D in the treatment of osteoporosis: where do we stand today?"],"prefix":"10.1007","volume":"15","author":[{"given":"Johann Diederich","family":"Ringe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,14]]},"reference":[{"issue":"6","key":"842_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785\u2013795. https:\/\/doi.org\/10.1001\/jama.285.6.785","journal-title":"JAMA"},{"key":"842_CR2","unstructured":"WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis : report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. WHO technical report series, vol 843. WHO, Geneva"},{"issue":"3","key":"842_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3):465\u2013475. https:\/\/doi.org\/10.1359\/jbmr.061113","journal-title":"J Bone Miner Res"},{"key":"842_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","volume":"8","author":"A Svedbom","year":"2013","unstructured":"Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA, IOF EURPo (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8:137. https:\/\/doi.org\/10.1007\/s11657-013-0137-0","journal-title":"Arch Osteoporos"},{"key":"842_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vhri.2015.09.007","volume":"9","author":"J Kim","year":"2016","unstructured":"Kim J, Lee E, Kim S, Lee TJ (2016) Economic burden of osteoporotic fracture of the elderly in South Korea: a national survey. Value Health Reg Issues 9:36\u201341. https:\/\/doi.org\/10.1016\/j.vhri.2015.09.007","journal-title":"Value Health Reg Issues"},{"key":"842_CR6","unstructured":"National Instituts of Health (2000) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement, vol 17. NIH, Kensington MD"},{"issue":"7316","key":"842_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/bmj.323.7316.795","volume":"323","author":"TJ Wilkin","year":"2001","unstructured":"Wilkin TJ, Devendra D (2001) Bone densitometry is not a good predictor of hip fracture. BMJ 323(7316):795\u2013797. https:\/\/doi.org\/10.1136\/bmj.323.7316.795","journal-title":"BMJ"},{"issue":"2","key":"842_CR8","first-page":"11","volume":"8","author":"PT Leali","year":"2011","unstructured":"Leali PT, Muresu F, Melis A, Ruggiu A, Zachos A, Doria C (2011) Skeletal fragility definition. Clin Cases Miner Bone Metab 8(2):11\u201313","journal-title":"Clin Cases Miner Bone Metab"},{"key":"842_CR9","volume-title":"Osteoporosis: assessing the risk of fragility fracture","author":"Guideline Development Group (GDG)","year":"2012","unstructured":"Guideline Development Group (GDG) (2012) Osteoporosis: assessing the risk of fragility fracture. NICE short clinical guideline, London"},{"issue":"10","key":"842_CR10","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis F (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359\u20132381. https:\/\/doi.org\/10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"issue":"2","key":"842_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11926-008-0020-y","volume":"10","author":"N Khazai","year":"2008","unstructured":"Khazai N, Judd SE, Tangpricha V (2008) Calcium and vitamin D: skeletal and extraskeletal health. Curr Rheumatol Rep 10(2):110\u2013117","journal-title":"Curr Rheumatol Rep"},{"key":"842_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.vh.2015.11.001","volume":"100","author":"HF DeLuca","year":"2016","unstructured":"DeLuca HF (2016) Vitamin D: historical overview. Vitam Horm 100:1\u201320","journal-title":"Vitam Horm"},{"issue":"3","key":"842_CR13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0889-857X(21)00359-8","volume":"20","author":"DD Bikle","year":"1994","unstructured":"Bikle DD (1994) Role of vitamin D, its metabolites, and analogs in the management of osteoporosis. Rheum Dis Clin N Am 20(3):759\u2013775","journal-title":"Rheum Dis Clin N Am"},{"issue":"10169","key":"842_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393(10169):364\u2013376. https:\/\/doi.org\/10.1016\/S0140-6736(18)32112-3","journal-title":"Lancet"},{"issue":"11","key":"842_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166(11):818\u2013839. https:\/\/doi.org\/10.7326\/M15-1361","journal-title":"Ann Intern Med"},{"key":"842_CR16","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1001\/jama.1941.02820220007002","volume":"116","author":"F Albright","year":"1941","unstructured":"Albright F, Smith PH, Richardson AM (1941) Postmenopausal osteoporosis. J Am Med Assoc 116:2465\u20132474","journal-title":"J Am Med Assoc"},{"issue":"6","key":"842_CR17","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1210\/jc.2010-0918","volume":"95","author":"JC Gallagher","year":"2010","unstructured":"Gallagher JC, Sai AJ (2010) Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab 95(6):2630\u20132633. https:\/\/doi.org\/10.1210\/jc.2010-0918","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"842_CR18","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1210\/jcem-51-6-1359","volume":"51","author":"JC Gallagher","year":"1980","unstructured":"Gallagher JC, Riggs BL, DeLuca HF (1980) Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab 51(6):1359\u20131364. https:\/\/doi.org\/10.1210\/jcem-51-6-1359","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"842_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.rcl.2010.02.014","volume":"48","author":"BL Clarke","year":"2010","unstructured":"Clarke BL, Khosla S (2010) Physiology of bone loss. Radiol Clin N Am 48(3):483\u2013495. https:\/\/doi.org\/10.1016\/j.rcl.2010.02.014","journal-title":"Radiol Clin N Am"},{"key":"842_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/bonekey.2013.227","volume":"3","author":"M van Driel","year":"2014","unstructured":"van Driel M, van Leeuwen JP (2014) Vitamin D endocrine system and osteoblasts. Bonekey Rep 3:493. https:\/\/doi.org\/10.1038\/bonekey.2013.227","journal-title":"Bonekey Rep"},{"issue":"5","key":"842_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1055\/s-2007-1018990","volume":"14","author":"B Lund","year":"1982","unstructured":"Lund B, Sorensen OH, Lund B, Agner E (1982) Serum 1,25-dihydroxyvitamin D in normal subjects and in patients with postmenopausal osteopenia. Influence of age, renal function and oestrogen therapy. Horm Metab Res 14(5):271\u2013274. https:\/\/doi.org\/10.1055\/s-2007-1018990","journal-title":"Horm Metab Res"},{"issue":"3","key":"842_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1172\/JCI109516","volume":"64","author":"JC Gallagher","year":"1979","unstructured":"Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF (1979) Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest 64(3):729\u2013736. https:\/\/doi.org\/10.1172\/JCI109516","journal-title":"J Clin Invest"},{"issue":"10","key":"842_CR23","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","volume":"20","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20(10):1633\u20131650. https:\/\/doi.org\/10.1007\/s00198-009-0920-3","journal-title":"Osteoporos Int"},{"issue":"5","key":"842_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1359\/jbmr.1998.13.5.763","volume":"13","author":"BL Riggs","year":"1998","unstructured":"Riggs BL, Khosla S, Melton LJ 3rd (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13(5):763\u2013773. https:\/\/doi.org\/10.1359\/jbmr.1998.13.5.763","journal-title":"J Bone Miner Res"},{"issue":"6","key":"842_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/joim.12825","volume":"284","author":"LM Smith","year":"2018","unstructured":"Smith LM, Gallagher JC, Kaufmann M, Jones G (2018) Effect of increasing doses of vitamin D on bone mineral density and serum N-terminal telopeptide in elderly women: a randomized controlled trial. J Intern Med 284(6):685\u2013693. https:\/\/doi.org\/10.1111\/joim.12825","journal-title":"J Intern Med"},{"issue":"11","key":"842_CR26","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(18)30265-1","volume":"6","author":"MJ Bolland","year":"2018","unstructured":"Bolland MJ, Grey A, Avenell A (2018) Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol 6(11):847\u2013858. https:\/\/doi.org\/10.1016\/S2213-8587(18)30265-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9471","key":"842_CR27","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/S0140-6736(05)63013-9","volume":"365","author":"AM Grant","year":"2005","unstructured":"Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, Anderson FH, Cooper C, Francis RM, Donaldson C, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA, Group RT (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365(9471):1621\u20131628. https:\/\/doi.org\/10.1016\/S0140-6736(05)63013-9","journal-title":"Lancet"},{"issue":"6","key":"842_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S2213-8587(17)30103-1","volume":"5","author":"KT Khaw","year":"2017","unstructured":"Khaw KT, Stewart AW, Waayer D, Lawes CMM, Toop L, Camargo CA Jr, Scragg R (2017) Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. Lancet Diabetes Endocrinol 5(6):438\u2013447. https:\/\/doi.org\/10.1016\/S2213-8587(17)30103-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"842_CR29","first-page":"13","volume":"24","author":"PH Anderson","year":"2003","unstructured":"Anderson PH, May BK, Morris HA (2003) Vitamin D metabolism: new concepts and clinical implications. Clin Biochem Rev 24(1):13\u201326","journal-title":"Clin Biochem Rev"},{"issue":"6","key":"842_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/00000441-198812000-00009","volume":"296","author":"NA Breslau","year":"1988","unstructured":"Breslau NA (1988) Normal and abnormal regulation of 1,25-(OH)2D synthesis. Am J Med Sci 296(6):417\u2013425. https:\/\/doi.org\/10.1097\/00000441-198812000-00009","journal-title":"Am J Med Sci"},{"issue":"3","key":"842_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1042\/cs0430413","volume":"43","author":"EB Mawer","year":"1972","unstructured":"Mawer EB, Backhouse J, Holman CA, Lumb GA, Stanbury SW (1972) The distribution and storage of vitamin D and its metabolites in human tissues. Clin Sci 43(3):413\u2013431. https:\/\/doi.org\/10.1042\/cs0430413","journal-title":"Clin Sci"},{"issue":"Pt B","key":"842_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jsbmb.2016.08.004","volume":"165","author":"MA Abbas","year":"2017","unstructured":"Abbas MA (2017) Physiological functions of vitamin D in adipose tissue. J Steroid Biochem Mol Biol 165(Pt B):369\u2013381. https:\/\/doi.org\/10.1016\/j.jsbmb.2016.08.004","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6 Suppl","key":"842_CR33","doi-asserted-by":"publisher","first-page":"1689S","DOI":"10.1093\/ajcn\/80.6.1689S","volume":"80","author":"HF DeLuca","year":"2004","unstructured":"DeLuca HF (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80(6 Suppl):1689S\u20131696S. https:\/\/doi.org\/10.1093\/ajcn\/80.6.1689S","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"842_CR34","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1210\/jc.2017-01187","volume":"102","author":"I Martinaityte","year":"2017","unstructured":"Martinaityte I, Kamycheva E, Didriksen A, Jakobsen J, Jorde R (2017) Vitamin D stored in fat tissue during a 5-year intervention affects serum 25-hydroxyvitamin D levels the following year. J Clin Endocrinol Metab 102(10):3731\u20133738. https:\/\/doi.org\/10.1210\/jc.2017-01187","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"842_CR35","first-page":"841","volume":"80","author":"P Bordelon","year":"2009","unstructured":"Bordelon P, Ghetu MV, Langan RC (2009) Recognition and management of vitamin D deficiency. Am Fam Physician 80(8):841\u2013846","journal-title":"Am Fam Physician"},{"issue":"3","key":"842_CR36","first-page":"373","volume":"95","author":"JC Gallagher","year":"1980","unstructured":"Gallagher JC, Riggs BL, Jerpbak CM, Arnaud CD (1980) The effect of age on serum immunoreactive parathyroid hormone in normal and osteoporotic women. J Lab Clin Med 95(3):373\u2013385","journal-title":"J Lab Clin Med"},{"issue":"6","key":"842_CR37","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.2779","volume":"31","author":"S Zaheer","year":"2016","unstructured":"Zaheer S, de Boer I, Allison M, Brown JM, Psaty BM, Robinson-Cohen C, Ix JH, Kestenbaum B, Siscovick D, Vaidya A (2016) Parathyroid hormone and the use of diuretics and calcium-channel blockers: the multi-ethnic study of atherosclerosis. J Bone Miner Res 31(6):1137\u20131145. https:\/\/doi.org\/10.1002\/jbmr.2779","journal-title":"J Bone Miner Res"},{"issue":"18","key":"842_CR38","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1001\/jama.2010.594","volume":"303","author":"KM Sanders","year":"2010","unstructured":"Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303(18):1815\u20131822. https:\/\/doi.org\/10.1001\/jama.2010.594","journal-title":"JAMA"},{"issue":"5","key":"842_CR39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00296-005-0073-4","volume":"26","author":"R Nuti","year":"2006","unstructured":"Nuti R, Bianchi G, Brandi ML, Caudarella R, D\u2019Erasmo E, Fiore C, Isaia GC, Luisetto G, Muratore M, Oriente P, Ortolani S (2006) Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int 26(5):445\u2013453. https:\/\/doi.org\/10.1007\/s00296-005-0073-4","journal-title":"Rheumatol Int"},{"key":"842_CR40","unstructured":"PRODUCT(2017) SUMMARY for Etalpha, capsules, soft. Leo PHARMA"},{"issue":"6","key":"842_CR41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199202063260601","volume":"326","author":"MW Tilyard","year":"1992","unstructured":"Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326(6):357\u2013362. https:\/\/doi.org\/10.1056\/NEJM199202063260601","journal-title":"N Engl J Med"},{"issue":"2","key":"842_CR42","first-page":"1061","volume":"4","author":"L Brandi","year":"2017","unstructured":"Brandi L (2017) Alfacalcidol in CKD-MBD - a fresh look. J Clin Nephrol Res 4(2):1061","journal-title":"J Clin Nephrol Res"},{"issue":"3","key":"842_CR43","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00296-012-2429-x","volume":"33","author":"JD Ringe","year":"2013","unstructured":"Ringe JD, Farahmand P, Schacht E (2013) Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients. Rheumatol Int 33(3):637\u2013643. https:\/\/doi.org\/10.1007\/s00296-012-2429-x","journal-title":"Rheumatol Int"},{"issue":"2","key":"842_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00296-007-0422-6","volume":"28","author":"JD Ringe","year":"2007","unstructured":"Ringe JD, Schacht E (2007) Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Rheumatol Int 28(2):103\u2013111. https:\/\/doi.org\/10.1007\/s00296-007-0422-6","journal-title":"Rheumatol Int"},{"issue":"1","key":"842_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12020-015-0606-x","volume":"50","author":"L Cianferotti","year":"2015","unstructured":"Cianferotti L, Cricelli C, Kanis JA, Nuti R, Reginster JY, Ringe JD, Rizzoli R, Brandi ML (2015) The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine 50(1):12\u201326. https:\/\/doi.org\/10.1007\/s12020-015-0606-x","journal-title":"Endocrine"},{"issue":"2","key":"842_CR46","first-page":"169","volume":"6","author":"L Cavalli","year":"2009","unstructured":"Cavalli L, Cavalli T, Marcucci G, Falchetti A, Masi L, Brandi ML (2009) Biological effects of various regimes of 25-hydroxyvitamin D3 (calcidiol) administration on bone mineral metabolism in postmenopausal women. Clin Cases Miner Bone Metab 6(2):169\u2013173","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"1","key":"842_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, the Committees of Scientific A, National Societies of the International Osteoporosis F (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"issue":"3","key":"842_CR48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1525-139X.2010.00722.x","volume":"23","author":"G Jones","year":"2010","unstructured":"Jones G (2010) Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analogs. Semin Dial 23(3):239\u2013243. https:\/\/doi.org\/10.1111\/j.1525-139X.2010.00722.x","journal-title":"Semin Dial"},{"key":"842_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1507\/endocrj.43.211","volume":"43","author":"M Shiraki","year":"1996","unstructured":"Shiraki M, Kushida K, Yamazaki K, Nagai T, Inoue T, Orimo H (1996) Effects of 2 years\u2019 treatment of osteoporosis 1 ci-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 43:211\u2013220","journal-title":"Endocr J"},{"key":"842_CR50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/BF01623386","volume":"6","author":"RMB Francis","year":"1996","unstructured":"Francis RMB, Boyle IT, Moniz C, Sutcliffe AM, Davis BS, Beastall GH, Cowan RA, Downes N (1996) A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int 6:284\u2013290","journal-title":"Osteoporos Int"},{"key":"842_CR51","first-page":"7","volume-title":"Vitamin D: molecular, cellular and clinical Endocrinology","author":"R Francis","year":"1988","unstructured":"Francis R, Robinson C, Davison C, Rodgers A (1988) The short term effects of alfacaicidol in elderly osteoporotic women. In: Norman AW, Schaefer K, Grigoleit H-G, Herrath D (eds) Vitamin D: molecular, cellular and clinical Endocrinology, vol 846. Waiter de Gruyter, Berlin, p 7"},{"issue":"6","key":"842_CR52","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2265.1980.tb01373.x","volume":"12","author":"HN Cohen","year":"1980","unstructured":"Cohen HN, Farrah D, Fogelman I, Goll CC, Beastall GH, McIntosh WB, Fletcher M, Boyle IT (1980) A low dose regime of 1 alpha hydroxyvitamin D3 in the management of senile osteoporosis: a pilot study. Clin Endocrinol 12(6):537\u2013542. https:\/\/doi.org\/10.1111\/j.1365-2265.1980.tb01373.x","journal-title":"Clin Endocrinol"},{"issue":"4","key":"842_CR53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s002239900708","volume":"65","author":"JD Ringe","year":"1999","unstructured":"Ringe JD, Coster A, Meng T, Schacht E, Umbach R (1999) Treatment of glucocorticoid-induced osteoporosis with alfacalcidol\/calcium versus vitamin D\/calcium. Calcif Tissue Int 65(4):337\u2013340. https:\/\/doi.org\/10.1007\/s002239900708","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"842_CR54","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","volume":"19","author":"H Fleisch","year":"1998","unstructured":"Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19(1):80\u2013100. https:\/\/doi.org\/10.1210\/edrv.19.1.0325","journal-title":"Endocr Rev"},{"issue":"5","key":"842_CR55","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00774-016-0792-5","volume":"35","author":"K Ebina","year":"2017","unstructured":"Ebina K, Kashii M, Hirao M, Hashimoto J, Noguchi T, Koizumi K, Kitaguchi K, Matsuoka H, Iwahashi T, Tsukamoto Y, Yoshikawa H (2017) Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis. J Bone Miner Metab 35(5):571\u2013580. https:\/\/doi.org\/10.1007\/s00774-016-0792-5","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"842_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N, National Osteoporosis Guideline G (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12(1):43. https:\/\/doi.org\/10.1007\/s11657-017-0324-5","journal-title":"Arch Osteoporos"},{"issue":"8","key":"842_CR57","first-page":"12935","volume":"8","author":"HB Shao","year":"2015","unstructured":"Shao HB, Yao YM, Wang ZY, Zhang QF, Wei W (2015) Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis. Int J Clin Exp Med 8(8):12935\u201312941","journal-title":"Int J Clin Exp Med"},{"issue":"8","key":"842_CR58","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"18","key":"842_CR59","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, Trial HPF (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"issue":"19","key":"842_CR60","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441. https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"issue":"9041","key":"842_CR61","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535\u20131541. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2","journal-title":"Lancet"},{"issue":"11","key":"842_CR62","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, Fracture Intervention T (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118\u20134124. https:\/\/doi.org\/10.1210\/jcem.85.11.6953","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"842_CR63","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077\u20132082. https:\/\/doi.org\/10.1001\/jama.280.24.2077","journal-title":"JAMA"},{"issue":"1","key":"842_CR64","first-page":"S20(P112)","volume":"17","author":"K Ones","year":"2006","unstructured":"Ones K, Schacht E (2006) Superiority of a combined treatment of alfacalcidol and alendronate compared to the monotherapies in postmenopausal osteoporosis. Osteoporos Int 17(1):S20(P112)","journal-title":"Osteoporos Int"},{"issue":"5","key":"842_CR65","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","volume":"27","author":"JD Ringe","year":"2007","unstructured":"Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27(5):425\u2013434. https:\/\/doi.org\/10.1007\/s00296-006-0288-z","journal-title":"Rheumatol Int"},{"issue":"2","key":"842_CR66","first-page":"174","volume":"7","author":"E Schacht","year":"2007","unstructured":"Schacht E, Dukas L, Richy F (2007) Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J Musculoskelet Neuronal Interact 7(2):174\u2013184","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"1","key":"842_CR67","first-page":"34","volume":"11","author":"D Felsenberg","year":"2011","unstructured":"Felsenberg D, Bock O, Borst H, Armbrecht G, Beller G, Degner C, Stephan-Oelkers M, Schacht E, Mazor Z, Hashimoto J, Roth HJ, Martus P, Runge M (2011) Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. J Musculoskelet Neuronal Interact 11(1):34\u201345","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"6","key":"842_CR68","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1185\/03007995.2011.580341","volume":"27","author":"H Orimo","year":"2011","unstructured":"Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M, group ATr (2011) Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. Curr Med Res Opin 27(6):1273\u20131284. https:\/\/doi.org\/10.1185\/03007995.2011.580341","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"842_CR69","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637\u2013645. https:\/\/doi.org\/10.1001\/jama.282.7.637","journal-title":"JAMA"},{"issue":"3","key":"842_CR70","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00774-011-0325-1","volume":"30","author":"I Gorai","year":"2012","unstructured":"Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30(3):349\u2013358. https:\/\/doi.org\/10.1007\/s00774-011-0325-1","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"842_CR71","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrendo.2016.164","volume":"13","author":"RA Lobo","year":"2017","unstructured":"Lobo RA (2017) Hormone-replacement therapy: current thinking. Nat Rev Endocrinol 13(4):220\u2013231. https:\/\/doi.org\/10.1038\/nrendo.2016.164","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"842_CR72","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00774-005-0639-y","volume":"24","author":"H Mizunuma","year":"2006","unstructured":"Mizunuma H, Shiraki M, Shintani M, Gorai I, Makita K, Itoga S, Mochizuki Y, Mogi H, Iwaoki Y, Kosha S, Yasui T, Ishihara O, Kurabayashi T, Kasuga Y, Hayashi K (2006) Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss. J Bone Miner Metab 24(1):11\u201315. https:\/\/doi.org\/10.1007\/s00774-005-0639-y","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"842_CR73","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1210\/edrv.22.4.0437","volume":"22","author":"P Lips","year":"2001","unstructured":"Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22(4):477\u2013501. https:\/\/doi.org\/10.1210\/edrv.22.4.0437","journal-title":"Endocr Rev"},{"issue":"9","key":"842_CR74","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032\u20131045. https:\/\/doi.org\/10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"842_CR75","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00296-003-0361-9","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24(2):63\u201370. https:\/\/doi.org\/10.1007\/s00296-003-0361-9","journal-title":"Rheumatol Int"},{"issue":"7","key":"842_CR76","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jbmr.1606","volume":"27","author":"EV McCloskey","year":"2012","unstructured":"McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27(7):1480\u20131486. https:\/\/doi.org\/10.1002\/jbmr.1606","journal-title":"J Bone Miner Res"},{"issue":"4 Suppl 1","key":"842_CR77","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0026-0495(90)90271-D","volume":"39","author":"T Fujita","year":"1990","unstructured":"Fujita T (1990) Studies of osteoporosis in Japan. Metabolism 39(4 Suppl 1):39\u201342","journal-title":"Metabolism"},{"issue":"5","key":"842_CR78","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/bf00305521","volume":"54","author":"H Orimo","year":"1994","unstructured":"Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N (1994) Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54(5):370\u2013376. https:\/\/doi.org\/10.1007\/bf00305521","journal-title":"Calcif Tissue Int"},{"issue":"54","key":"842_CR79","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3999\/jscpt.44.395","volume":"44","author":"M Nakano","year":"2013","unstructured":"Nakano M, Tsujimoto M, Sowa H (2013) The effect of the concomitant administration of active vitamin D on the safety of once-a-day subcutaneous injection of teriparatide 20\u03bcg\/day. Jpn J Clin Pharmacol Ther 44(54):395\u2013403","journal-title":"Jpn J Clin Pharmacol Ther"},{"issue":"6","key":"842_CR80","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00296-004-0523-4","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD (2004) Questions on the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24(6):370. https:\/\/doi.org\/10.1007\/s00296-004-0523-4","journal-title":"Rheumatol Int"},{"issue":"3","key":"842_CR81","first-page":"243","volume":"7","author":"ML Brandi","year":"2010","unstructured":"Brandi ML (2010) Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes. Clin Cases Miner Bone Metab 7(3):243\u2013250","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"6","key":"842_CR82","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/s8756-3282(97)00054-9","volume":"20","author":"JT Chen","year":"1997","unstructured":"Chen JT, Shiraki M, Hasumi K, Tanaka N, Katase K, Kato T, Hirai Y, Nakamura T, Ogata E (1997) 1-alpha-Hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 20(6):557\u2013562. https:\/\/doi.org\/10.1016\/s8756-3282(97)00054-9","journal-title":"Bone"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-020-00842-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11657-020-00842-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-020-00842-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T21:03:51Z","timestamp":1669583031000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11657-020-00842-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,14]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1007\/s11657-020-00842-0","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,14]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not relevant review of previously published studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Given.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Given.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"182"}}